Mail to a Friend |
|
Rate |
Akcea Therapeutics Canada, Inc., a subsidiary of Akcea Therapeutics, Inc. (NASDAQ: AKCA), announced that it has concluded its negotiation with the pan-Canadian Pharmaceutical Alliance (pCPA) with a Letter of Intent regarding TEGSEDI? (inoterson) for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR)1. Akcea Therapeutics, Inc. is a majority-owned affiliate of Ionis Pharmaceuticals, Inc.
For full article visit website.
Company :-Akcea Therapeutics Inc.
User :- Akcea Therapeutics
Email :-info.akceacanada@gmail.com
Url :- http://www.akceatx.ca/